Table 4. Protease Inhibitor (PI) Surveillance Drug Resistance Mutation (SDRM) List: 40 Mutations at 18 Positions* .
| Position | AA | New | Lists | A (%) | AE (%) | AG (%) | B (%) | C (%) | D (%) | F (%) | G (%) | No Rx (%) | Max Rx (%) |
| Number of individuals: | 1,528 | 902 | 1,437 | 7,439 | 2,182 | 515 | 598 | 619 | 15,220 | 7,886 | |||
| 23 | I | √ | 3 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 2.1 |
| 24 | I | 5 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0.2 | 0 | 0.2 | 11 | |
| 30 | N | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.0 | |
| 32 | I | 5 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0.1 | 7.3 | |
| 46 | I | 5 | 0.3 | 0.6 | 0.1 | 0.4 | 0.2 | 0 | 0.2 | 0 | 0.6 | 29 | |
| L | √ | 5 | 0.3 | 0.2 | 0.3 | 0.3 | 0.1 | 0.2 | 0.2 | 0.5 | 0.5 | 13 | |
| 47 | V | 5 | 0 | 0 | 0 | 0 | 0.1 | 0.2 | 0 | 0.3 | 0.3 | 6.8 | |
| A | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | ||
| 48 | V | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.7 | |
| M | √ | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.3 | |
| 50 | V | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | |
| L | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.8 | ||
| 53 | L | 5 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.2 | 7.8 | |
| Y | √ | 4 | 0.1 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0.6 | |
| 54 | V | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43 | |
| L | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.6 | ||
| M | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.3 | ||
| A | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | ||
| T | 5 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 1.7 | ||
| S | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.7 | ||
| 73 | S | 5 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0.1 | 13 | |
| T | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.3 | ||
| C | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.0 | ||
| A | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | ||
| 76 | V | √ | 5 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0.1 | 4.3 |
| 82 | A | 5 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0.2 | 0 | 0.2 | 30 | |
| T | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | ||
| F | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.1 | ||
| S | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.6 | ||
| C | √ | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | |
| M | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | ||
| L | √ | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | |
| 83 | D | √ | 3 | 0 | 0 | 0.1 | 0 | 0.1 | 0 | 0 | 0 | 0.1 | 9.3 |
| 84 | V | 5 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 21 | |
| A | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | ||
| C | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | ||
| 85 | V | √ | 4 | 0.1 | 0 | 0.1 | 0.1 | 0.2 | 0 | 0.2 | 0 | 0.2 | 6.4 |
| 88 | D | 5 | 0 | 0.1 | 0.1 | 0.1 | 0 | 0 | 0 | 0.2 | 0.2 | 6.4 | |
| S | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | ||
| 90 | M | 5 | 0.1 | 0.3 | 0 | 0.1 | 0.1 | 0 | 0 | 0.5 | 0.5 | 45 | |
| Sum of Prevalences: | 1.1 | 1.5 | 1.1 | 1.0 | 1.0 | 0.4 | 1.2 | 1.2 | |||||
Abbreviations: Pos – amino acid position; AA – amino acid difference from consensus B; Lists – Number of mutation lists with the mutation; New – mutations not present on the 2007 SDRM list; No Rx – highest prevalence in untreated persons in any of the 8 listed subtypes; Max Rx – Prevalence of the mutation in the subtype with the highest prevalence of the mutation provided the mutation is present in viruses from two or more individuals. Underlined bold mutations are those with a prevalence >0.5% that are nonetheless included because the >0.5% prevalence occurs in only one subtype with fewer than 1000 sequences or in fewer than 1000 sequences available for analysis.